Schrodinger (SDGR) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Schrodinger (SDGR) over the past year, gaining 495.3% versus a gain of 35.4%. Over five years, SLS leads with a +28.1% price change compared with -50.7% for SDGR. SELLAS Life Sciences Group is the larger company by market cap ($2.18 billion vs $1.96 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDGR | SLS |
|---|---|---|
| Share price | $26.16 | $10.81 |
| Market cap | $1.96B | $2.18B |
| 1-day change | -4.14% | -4.42% |
| YTD return | +52.63% | +200.00% |
| 1-year return | +35.37% | +495.26% |
| 5-year return | -50.70% | +28.09% |
| EPS (TTM) | $-0.74 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.78 | $15.88 |
| 52-week low | $10.95 | $1.39 |
| Distance from 52-week high | -22.56% | -31.93% |
| Analyst consensus | none | none |
| Avg. price target upside | -18.08% | +200.65% |
| Average volume | 1.74M | 6.56M |
| Shares outstanding | 65.64M | 201.95M |
| Employees | 850 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed SDGR by 459.9 percentage points over the past year.
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
SDGR vs SLS FAQ
Which is bigger, Schrodinger or SELLAS Life Sciences Group?
SELLAS Life Sciences Group (SLS) is larger, with a market capitalization of $2.18B compared with $1.96B for Schrodinger (SDGR).
Which stock has performed better over the past year, SDGR or SLS?
SLS returned +495.26% over the past 12 months, compared with +35.37% for SDGR (price return, excluding dividends). Past performance does not predict future results.
Are Schrodinger and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.